dc.contributor.author | Lyndon, Gavin J. | |
dc.contributor.author | Prieto, Rita | |
dc.contributor.author | Wajsbrot, Dalia B. | |
dc.contributor.author | Allgulander, Christer | |
dc.contributor.author | Bandelow, Borwin | |
dc.date.accessioned | 2019-11-25T11:03:56Z | |
dc.date.available | 2019-11-25T11:03:56Z | |
dc.date.issued | 2019 | de |
dc.relation.ISSN | 1473-5857 | de |
dc.identifier.uri | http://resolver.sub.uni-goettingen.de/purl?gs-1/16708 | |
dc.description.abstract | Effects of baseline anxiety on the efficacy of venlafaxine extended release versus placebo were examined in a post hoc pooled subgroup analysis of 1573 patients enrolled in eight short-term studies of major depressive disorder. Anxiety subgroups were defined based on baseline 17-item Hamilton Rating Scale for Depression Item 10 score <3 (low) versus ≥3 (high). Change from baseline to final visit in Montgomery-Åsberg Depression Rating Scale total score and Montgomery-Åsberg Depression Rating Scale response and remission rates were analyzed. Change from baseline in Montgomery-Åsberg Depression Rating Scale total score and response and remission rates was significantly greater for venlafaxine extended release versus placebo in both low and high anxiety subgroups (all P < 0.0001). A statistically significant baseline anxiety by treatment interaction was observed for Montgomery-Åsberg Depression Rating Scale total score only (P = 0.0152). The adjusted mean change from baseline in Montgomery-Åsberg Depression Rating Scale total score was significantly greater in the high anxiety subgroup versus low anxiety subgroup for patients treated with venlafaxine extended release (-6.27 versus -3.89; P = 0.0440) but not placebo. These results support the efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms. | de |
dc.language.iso | eng | de |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | anxiety, major depressive disorder, serotonin–norepinephrine reuptake inhibitor, treatment efficacy, venlafaxine extended release | de |
dc.subject.ddc | 612 | |
dc.title | Efficacy of venlafaxine extended release in major depressive disorder patients | de |
dc.type | journalArticle | de |
dc.identifier.doi | 10.1097/YIC.0000000000000256 | |
dc.type.version | publishedVersion | de |
dc.relation.pISSN | 0268-1315 | |
dc.bibliographicCitation.volume | 34 | de |
dc.bibliographicCitation.issue | 3 | de |
dc.bibliographicCitation.firstPage | 110 | de |
dc.bibliographicCitation.lastPage | 118 | de |
dc.type.subtype | journalArticle | |
dc.identifier.pmid | 30870236 | |
dc.description.status | peerReviewed | de |
dc.bibliographicCitation.journal | International Clinical Psychopharmacology | de |
dc.title.subtitle | effect of baseline anxiety symptom severity | |